Detalhe da pesquisa
1.
Antisense Inhibition of Prekallikrein to Control Hereditary Angioedema.
N Engl J Med
; 383(13): 1242-1247, 2020 09 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-32877578
2.
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.
N Engl J Med
; 382(3): 244-255, 2020 01 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-31893580
3.
Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy.
JAMA
; 330(15): 1448-1458, 2023 10 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37768671
4.
Population pharmacokinetic/pharmacodynamic modelling of eplontersen, an antisense oligonucleotide in development for transthyretin amyloidosis.
Br J Clin Pharmacol
; 88(12): 5389-5398, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35869634
5.
Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis.
J Lipid Res
; 60(12): 2082-2089, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31551368
6.
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.
N Engl J Med
; 373(5): 438-47, 2015 Jul 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-26222559
7.
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
Lancet
; 388(10057): 2239-2253, 2016 11 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27665230
8.
Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.
Lancet
; 386(10002): 1472-83, 2015 Oct 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26210642
9.
Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen.
Neurol Ther
; 12(1): 267-287, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36525140
10.
Prevalence and influence of LPA gene variants and isoform size on the Lp(a)-lowering effect of pelacarsen.
Atherosclerosis
; 324: 102-108, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33872986
11.
Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data.
ESC Heart Fail
; 8(1): 652-661, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33283485
12.
Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy.
Neurol Ther
; 10(1): 375-389, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33638113
13.
Integrated Assessment of the Clinical Performance of GalNAc3-Conjugated 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience.
Nucleic Acid Ther
; 29(1): 16-32, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30570431
14.
IONIS-PKKRx a Novel Antisense Inhibitor of Prekallikrein and Bradykinin Production.
Nucleic Acid Ther
; 29(2): 82-91, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30817230
15.
Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide.
J Clin Lipidol
; 12(3): 702-710, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29574075
16.
Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size.
J Clin Lipidol
; 12(5): 1313-1323, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30100157
17.
Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx and IONIS-APO(a)-LRx antisense oligonucleotide clinical trials.
J Clin Lipidol
; 12(1): 122-129.e2, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29174389